OGN News and Press, Organon & Co. From 06/30/22

Daré will receive a $10 million upfront payment from Organon An estimated 21 million American women experience bacterial vaginosis SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, ...

DON is a dividend mid-cap ETF with a monthly distribution. 23% of asset value is in financials. Past performance shows no edge over a mid-cap benchmark. For further details see: DON: Mid-Cap Dividend ETF Review

The pharmaceutical/biotechnology subsector has the best value and quality scores. Healthcare equipment is the most overvalued industry. IHF: a concentrated ETF in healthcare providers. 10 stocks cheaper than their peers in June. For further details see: IHF: Healthca...

Organon's P/E ratio was 6.5 at the end of Q1 2022, significantly lower than the pharmaceutical industry average. Viatris' revenue was $4,191.7 million in the first quarter of 2022, down 5.4% from a year earlier. Viatris' generic and brand drug sales have been declining year on yea...

Unofficial sources said Joincare would seek to raise around $300 to $400 million. META Pharma of Shenzhen raised $15 million in Seed and Pre-A rounds to fund its immunometabolism-based small-molecule drug discovery operations. CANbridge, a Beijing-Cambridge MA rare disease/rare on...

Women’s health company Organon (NYSE:OGN) announced on Monday an agreement with Chinese biopharmaceutical company Shanghai Henlius Biotech, Inc. (OTCPK:SGBCF) for commercialization of two biosimilar candidates targeted at conditions such as breast cancer and osteoporosis. Pertuzumab is...

Collaboration expands and underscores commitment to biosimilars portfolio and focus on women’s health with biosimilar candidates for osteoporosis and breast cancer Organon (NYSE: OGN), a global women’s health company with deep expertise in biosimilar commercial...

BofA Securities is out with a list of stocks that should benefit from a transforming world. "The changing composition of the global population in the decades to come will be transformational," BofA analysts wrote in a note. "The global population has doubled in the past 50 years, but declinin...

The U.S. Food and Drug Administration (FDA) has for the first time required labeling changes to the popular anti-baldness pill Propecia marketed by Organon (NYSE:OGN) to reflect the risk of suicidal behavior in men taking the drug. Previously, the FDA has required labeling changes to the medi...

On One Year Anniversary, Organon Introduces Global Environmental, Social and Governance (ESG) Strategy and Commitments with Publication of Inaugural ESG Report Canada NewsWire Report lays out blueprint for achieving Organon's purpose and business imperatives to help wo...